A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy - LOTOS

Exclusion Criteria

• - Participant with mixed SCLC and NSCLC histology.
• - Brain metastases or spinal cord compression unless the participant is stable and off steroids.
• - Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.
• - Active or prior documented autoimmune or inflammatory disorders.
• - History of leptomeningeal carcinomatosis.
• - Participants who have received more than one line of prior anti-PD-(L)1.
• - Participants must not have experienced a toxicity that led to discontinuation of the prior anti-PD(L)1 therapy.
• - Participants must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
• - Participants must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged.
• - Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.
• - As judged by the investigator, any evidence of medical condition, which, in the investigator’s opinion, makes it undesirable for the participant to participate in the study.
• - Participants who have received a prior ATR inhibitor.
• - Diagnosis of ataxia telangiectasia.